---
document_datetime: 2025-09-26 16:05:15
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/prasugrel-viatris-previously-prasugrel-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: prasugrel-viatris-previously-prasugrel-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.0335169
conversion_datetime: 2025-12-19 04:47:30.659952
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Prasugrel Viatris

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                       | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|-----------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| VariationtypeIA/    | A.ADMINISTRATIVECHANGES-A.7 | 22/09/2025                          |                                          | Annex II and                    |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | Deletionofmanufacturingsitesforanactive substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place,orsupplierofastartingmaterial, reagent or excipient (when mentioned in the dossier)*- Accepted                                                                                                                                                                                                                                                                                  |            | PL              | EMA/VR/0000296778   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------|---------------------|
| Variation typeIB/ EMA/VR/0000292271   | B.II.e)Container closure system-B.II.e.z Othervariation-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 11/09/2025 |                 |                     |
| Variation type IB / EMA/VR/0000256926 | C.1.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan-C.I.11.z Other RMP changes (e.g. agreed wording + template change)-Accepted C.1.11.z (Type IB) - To update the RMP in accordancewiththepublishedRMPof the referenceproductEfient,following the adoptionofthesamechangesappliedfor. AnnexIIoftheProductInformationhas beenupdatedaccordingly.TheMAHtookthe opportunity to update the contact details of the local representative in Cyprus in section 6 of thePackageLeaflet. | 30/05/2025 | Annex II and PL |                     |
| Article 61(3) /                       | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 20/03/2025 | PL              | EMA/N/0000247565    |

<div style=\"page-break-after: always\"></div>

|                                       | contactdetailsoflocalrepresentativesand deletion of'UnitedKingdom(Northern Ireland)' from the list of local representativesinlinewith theQRD template v10.4.                                                                                                                                                                                                                                                                                                                                       |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000248723 | A.ADMINISTRATIVECHANGES-A.4Change in the name and/or address of: a manufacturer(including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagent orintermediate usedinthemanufactureof theactive substance(wherespecifiedin thetechnical dossier)where noPh.Eur.Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier)- Accepted | 07/02/2025 | N/A |